Home' Clinical Aesthetics : CA issue 4 Contents TRENDING
A report by Allergan, the makers of Botox
and Juvederm dermal fillers, has revealed
women’s attitudes to beauty across the globe.
The Changing Faces of Beauty: A Global
Report 2016 was commissioned by Allergan
and conducted by Insight Engineers via
an online questionnaire, sur veying 7700
“ae sthetically aware” respondent s.
Among the findings, 59% of respondents
said double chins were their biggest hang up.
So the good news is that in May
a “game changer” in non-surgical,
injectable aesthetic solutions – leading
Australian cosmetic physicians such as
Drs Irene Kushelew, Cath Porter and
Naomi McCullum have informed Clinical
Aesthetics – will be rolled out in Australia.
Belkyra (known as Kybella elsewhere) has
been the subject of extensive global clinical
trials and was the star turn of the Allergan
conference in Sydney in February.
In brief, it is a progressive injectable
solution for submental fat, breaking down
fat cells, resulting in a more contoured
and improved profile, thus reducing the
appearance of jowls and “turkey gobblers”
in suitable candidates.
In said suitable candidates, it
may negate the need for surgical
inter vention, such as liposuction and/or
We will give you all the details of Belkyra
in the next issue of Clinical Aesthetics, but
in this issue we concentrate on the need for
extensive training to be able to perform the
procedure; as well as ongoing training in
general (See Page 30).
And it offers yet another solution for
su fferers of Tech Neck!
Eye rejuvenation is one of the most popularly requested cosmetic
medical treatments, but it is also notoriously hard to create
significant improvement without blepharoplasty.
Ever-evolving non-surgical technology is, however, changing
the landscape. A couple of examples:
Thermage RF on the upper and lower eyelids is a highly
specialised technique requiring the utmost skill, and performed
thus far by only a handful of medical practitioners in Australia.
A defibrillator for the dermis, of sorts, it combines heat
energy to treat deep tissue and a cooling effect to protect the
skin surface and provide optimal patient comfort. It takes about
This editor had it performed in October last year by Katherine
Millar- Shannon, cosmetic nurse practitioner and owner of
Duquessa medispas in Melbourne and Sydney.
Over ensuing weeks I began to notice subtle, progressive
differences to the hooding/crepeing of my upper lids
(particularly noticeable when I applied eyeshadow).
The lines, wrinkles and dark circles also started to diminish,
but I was more heartened by the lifting/firming effect, as
hooding and under-eye bagging had given me a tired, and
somewhat worried or cranky look.
Katherine told me I could expect to see real results in
February/March. And so it transpired. One day a couple of weeks
ago it seemingly just “happened ”.
Another non- surgical breakthrough for eye lifting is the
Agnes RF device from Korea, for treating bags and deep lines,
among other skin conditions.
“ The surgical removal of lower eyelid fat bags is, besides the
expense, technically difficult with a common complication being
a sunken appearance to the eye,” says cosmetic physician Dr
Adam Rish, based in Sydney’s Bondi Junction.
The Agnes uses a fine- coated needle to dissolve the fat pad in
a precisely controlled manner. The use of a shallower needle then
tightens lower eye connective tissue to f latten the bag back into
the orbit. It may also be used for chin fat pads.
Agnes RF procedures depend on targeted tissue. Most can be
done in 15 minutes and recovery time is 3 -7 days, with swelling
and redness followed by a further week of less severe redness.
Camouflage makeup may be used to cover eye bag treatments by
around Day 3.
Benefits appear over the next few months as new collagen
is deposited under the skin and the fat is removed by the
Results of a single treatment should be permanent but 2-3
treatments may be needed to maximise improvement.
DUQUESSA.COM.AU; THERMAGE.NET.AU; KOSMEDICAL.COM.AU
(FOR AGNES RF)
CLINICAL AESTHETICS | 5
Links Archive CA issue - 3 CA Issue 5 Navigation Previous Page Next Page